Skip to main content

Quest Diagnostics ownership: holders and insider trading

  • DGX · NYSE
  • Healthcare
  • Health Care Services
  • S&P 500
$262.21+1.01%Close 16 Nov 2026 · Market value $28.35B

As filed, its directors and officers own 0.9% of the shares (proxy statement, 6 Mar 2026); 1,095 institutional managers reported holding 95.4% at 30 Jun 2026. Over the last twelve months, insiders sold $48.85M of shares on the open market, $48.07M of it under 10b5-1 plans set in advance, and bought none.

From the company's proxy statement, each holder's latest Schedule 13D or 13G, the institutional managers' quarterly 13F reports and the insiders' Form 4 filings. A percentage is shown as filed; one marked * is worked out here from the shares outstanding.

Largest holders

HolderTypeSharesOf the companySourceAs of
VanguardInstitution14.6M13.23%*Form 13F30 Jun 2026
BlackRock, Inc.Holder9.3M8.43%*Form 13F30 Jun 2026
Vanguard Capital ManagementHolder8.3M7.53%Schedule 13G31 Mar 2026
Vanguard Portfolio ManagementHolder6.1M5.54%Schedule 13G31 Mar 2026
State StreetInstitution5.6M5%Schedule 13G30 Sep 2026
T. Rowe Price Associates, Inc.Holder5.4M4.95%*Form 13F30 Jun 2026
Boston PartnersInstitution4.7M4.31%*Form 13F30 Jun 2026
JPMorgan ChaseInstitution3.5M3.20%*Form 13F30 Jun 2026
Geode Capital ManagementInstitution3.1M2.85%*Form 13F30 Jun 2026
Morgan StanleyInstitution2.5M2.24%*Form 13F30 Jun 2026
EdgePoint Investment Group Inc.Institution2.2M2.04%*Form 13F30 Jun 2026
Dimensional Fund AdvisorsInstitution2.0M1.81%*Form 13F30 Jun 2026
Bank of AmericaInstitution1.9M1.76%*Form 13F30 Jun 2026
Grantham, Mayo, Van Otterloo & Co. LLCInstitution1.9M1.72%*Form 13F30 Jun 2026
UBSInstitution1.8M1.66%*Form 13F30 Jun 2026
Wells FargoInstitution1.8M1.59%*Form 13F30 Jun 2026
Davis Selected AdvisersInstitution1.6M1.41%*Form 13F30 Jun 2026
Victory Capital Management IncInstitution1.6M1.41%*Form 13F30 Jun 2026
Norges BankInstitution1.4M1.28%*Form 13F30 Jun 2026
Fidelity (FMR)Institution1.4M1.27%*Form 13F30 Jun 2026

Insider transactions latest 25

InsiderDateTransactionSharesPriceValue
Deppe Michael J · SVP, Corp. Controller & CAO13 Nov 2026Option exercise+6.3K$95.80$599.8K
Deppe Michael J · SVP, Corp. Controller & CAO13 Nov 2026Open-market sale (10b5-1 plan)−6.3K$260.17$1.63M
Deppe Michael J · SVP, Corp. Controller & CAO13 Nov 2026Option exercise+5.5K$103.57$571.2K
Deppe Michael J · SVP, Corp. Controller & CAO13 Nov 2026Open-market sale (10b5-1 plan)−5.5K$260.17$1.43M
Plewman Patrick · SVP for Diagnostic Services9 Nov 2026Option exercise+4.3K$127.72$545.9K
Plewman Patrick · SVP for Diagnostic Services9 Nov 2026Open-market sale (10b5-1 plan)−4.3K$257.34$1.10M
Plewman Patrick · SVP for Diagnostic Services9 Nov 2026Option exercise+6.8K$127.81$868.2K
Plewman Patrick · SVP for Diagnostic Services9 Nov 2026Open-market sale (10b5-1 plan)−6.8K$257.34$1.75M
Plewman Patrick · SVP for Diagnostic Services9 Nov 2026Open-market sale (10b5-1 plan)−650$257.34$167.3K
Ramachandran Subu · SVP, Regional Businesses3 Nov 2026Grant or award+352——
Doherty Catherine T. · Executive Vice President3 Nov 2026Grant or award+4.8K——
Doherty Catherine T. · Executive Vice President3 Nov 2026Option exercise+22.1K$121.81$2.69M
Doherty Catherine T. · Executive Vice President3 Nov 2026Open-market sale (10b5-1 plan)−3.8K$245.45$937.1K
Doherty Catherine T. · Executive Vice President3 Nov 2026Open-market sale (10b5-1 plan)−6.0K$246.26$1.48M
Doherty Catherine T. · Executive Vice President3 Nov 2026Open-market sale (10b5-1 plan)−1.2K$246.98$284.3K
Doherty Catherine T. · Executive Vice President3 Nov 2026Open-market sale (10b5-1 plan)−2.4K$248.38$585.7K
Doherty Catherine T. · Executive Vice President3 Nov 2026Open-market sale (10b5-1 plan)−3.0K$249.40$749.2K
Doherty Catherine T. · Executive Vice President3 Nov 2026Open-market sale (10b5-1 plan)−2.9K$250.49$720.7K
Doherty Catherine T. · Executive Vice President3 Nov 2026Open-market sale (10b5-1 plan)−2.9K$251.24$730.4K
DELANEY MARK E · SVP & Chief Commercial Officer3 Nov 2026Grant or award+2.6K——
PFEIFFER GARY M · Director26 Oct 2026Open-market sale (10b5-1 plan)−1.2K$243.00$292.3K
SAMAD SAM · Executive Vice President & CFO21 Oct 2026Grant or award+90$235.94$21.23K
Gregg Vicky B · Director21 Oct 2026Grant or award+63$235.94$14.86K
Davis J. E. · CEO and President · Director1 Sep 2026Open-market sale (10b5-1 plan)−10.0K$242.72$2.43M
PREVOZNIK MICHAEL E · SVP & General Counsel28 Aug 2026Open-market sale (10b5-1 plan)−430$244.51$105.1K

Form 4 filings since 17 Nov 2024: purchases and sales, grants, option exercises and shares withheld for tax. Gifts and other transfers are left out.

DGX in the terminal

Holders over eight quarters by family, every Form 4 and Form 144 back two years, and alerts on insider buying.